COST-EFFECTIVENESS OF TISAGENLECLEUCEL IN PAEDIATRIC AND YOUNG ADULT RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBASTIC LEUKAEMIA, FROM A GREEK SOCIAL SECURITY SYSTEM PERSPECTIVE

被引：0
作者：
Kattamis, A. [1 ]
Avgitidou, A. [2 ]
Chatzopoulos, S. [2 ]
Markouri, A. [3 ]
Florini, S. [3 ]
Stafylas, P. [2 ]
机构：
[1] Univ Athens, Aghia Sophia Childrens Hosp, Dept Pediat 1, Athens, Greece
[2] HealThink, Thessaloniki, Greece
[3] Novartis, Athens A1, Greece
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN85
引用
收藏
页码：S452 / S452
页数：1
相关论文
共 50 条
[31]   Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia [J].
Sarkar, Reith R. ;
Gloude, Nicholas J. ;
Schiff, Deborah ;
Murphy, James D. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2019, 111 (07) :719-726
[32]   COST-EFFECTIVENESS OF THE BREXU-CEL IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA AND B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A SYSTEMATIC REVIEW [J].
Khatiwada, A. ;
Kamel, A. ;
Ngorsuraches, S. .
VALUE IN HEALTH, 2024, 27 (06) :S80-S80
[33]   MODELING APPROACHES IN COST-EFFECTIVENESS ANALYSES OF CELL THERAPIES FOR RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA [J].
Hernandez, L. G. ;
Martin, A. L. ;
Brouwer, E. S. ;
Chun, D. ;
Cheng, L., I ;
Bernhardt, A. .
VALUE IN HEALTH, 2022, 25 (01) :S53-S53
[34]   Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States [J].
Shah, Bijal D. ;
Smith, Nathaniel J. ;
Feng, Chaoling ;
Jeyakumar, Sushanth ;
Castaigne, Jean-Gabriel ;
Faghmous, Imi ;
Masouleh, Behzad Kharabi ;
Malone, Daniel C. ;
Bishop, Michael R. .
ADVANCES IN THERAPY, 2022, 39 (08) :3678-3695
[35]   COST-EFFECTIVENESS ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN BULGARIA [J].
Djambazov, S. ;
Slavchev, G. ;
Encheva-Malinova, M. ;
Varbanova, V. ;
Velchev, M. ;
Raduilov, B. ;
Vekov, T. .
VALUE IN HEALTH, 2018, 21 :S38-S38
[36]   COST-EFFECTIVENESS OF BLINATUMOMAB VERSUS STANDARD OF CARE IN ADULT PATIENTS WITH PHILADELPHIA-CHROMOSOME-POSITIVE RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA FROM A CANADIAN HEALTHCARE SECTOR PERSPECTIVE [J].
Delea, T. E. ;
Raman, K. ;
Boyko, D. ;
Moynahan, A. ;
Dirnberger, F. ;
Despiegel, N. ;
Tiwana, S. ;
Sapra, S. .
VALUE IN HEALTH, 2020, 23 :S36-S36
[37]   Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States [J].
Bijal D. Shah ;
Nathaniel J. Smith ;
Chaoling Feng ;
Sushanth Jeyakumar ;
Jean-Gabriel Castaigne ;
Imi Faghmous ;
Behzad Kharabi Masouleh ;
Daniel C. Malone ;
Michael R. Bishop .
Advances in Therapy, 2022, 39 :3678-3695
[38]   Cytopenias after Tisagenlecleucel in Paediatric/young Adult Patients with Refractory/relapse b-cell Acute Lymphoblastic Leukaemia (R/R B-all): A real-life Single-centre Experience [J].
Gomez-Centurion, Ignacio ;
Burridge, Saskia ;
Silva, Juliana ;
Lazareva, Arina ;
Gabelli, Maria ;
Mirci-Danicar, Oana ;
Lucchini, Giovanna ;
Chiesa, Robert ;
Rao, Kanchan ;
Samarasinghe, Sujith ;
Veys, Paul ;
Vora, Ajay ;
Amrolia, Persis ;
Ghorashian, Sara .
BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) :250-250
[39]   Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore's healthcare system perspective [J].
Cher, Boon Piang ;
Gan, Kar Yee ;
Aziz, Mohamed Ismail Abdul ;
Lin, Liang ;
Hwang, William Ying Khee ;
Poon, Li Mei ;
Ng, Kwong .
JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (11) :1321-1329
[40]   Cost-effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma. [J].
Lin, John ;
Muffly, Lori S. ;
Spinner, Michael Alexander ;
Barnes, James I. ;
Owens, Douglas K. ;
Goldhaber-Fiebert, Jeremy D. .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345